Sanofi-owned Aventis Pharma has received approval for its type 1 diabetes (T1D) drug, Tzield (teplizumab), from the UK Medicines and Healthcare products Regulatory Agency (MHRA). This authorisation ...

The application seeks approval for Tzield (teplizumab-mzwv) to delay the progression of stage 3 type 1 diabetes in adults and pediatric patients eight years and older who have been recently diagnosed ...

Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes Approval based on the TN-10 study, demonstrating Tzield’s ability to delay the ...

Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes Approval based on the TN-10 study, demonstrating Tzield’s ability to delay the ...

The U.S. Food and Drug Administration has approved a supplemental biologics license application for Sanofi’s (SNY) Tzield (teplizumab-mzwv), expanding its use to patients as young as one year old to ...

What Is Tzield, and Why Does It Matter? Tzield (teplizumab-mzwv) is an immune therapy that can help delay the progression of type 1 diabetes (T1D) in people who are at high risk. The FDA has now ...